<DOC>
	<DOC>NCT02711423</DOC>
	<brief_summary>This two-part study is designed to assess the safety, tolerability, and PK of gantenerumab in healthy volunteers. Part I (dose escalation) will randomly assign participants to receive a single blinded SC dose of gantenerumab or placebo. Part II (PK extension) will randomly assign participants to receive a single open-label SC dose of ganenerumab at different dose levels according to safety assessments from Part I.</brief_summary>
	<brief_title>A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Healthy males 18 to 45 years of age, inclusive Body mass index (BMI) 20.0 to 32.0 kilograms per metersquared (kg/m^2), inclusive History of cancer or any clinically significant disease affecting one of the major organ systems Prior administration of gantenerumab Clinically significant laboratory test results Clinically relevant history of hypersensitivity or allergic reaction following exposure to a drug, food, or environmental agent Known hypersensitivity to gantenerumab or excipients of study drug formulation Abnormal skin condition or potentially obscuring tattoo, pigmentation, or lesion in the area intended for SC injection Familial history of earlyonset Alzheimer's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>